RU2657535C2 - Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act) - Google Patents

Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act) Download PDF

Info

Publication number
RU2657535C2
RU2657535C2 RU2014139668A RU2014139668A RU2657535C2 RU 2657535 C2 RU2657535 C2 RU 2657535C2 RU 2014139668 A RU2014139668 A RU 2014139668A RU 2014139668 A RU2014139668 A RU 2014139668A RU 2657535 C2 RU2657535 C2 RU 2657535C2
Authority
RU
Russia
Prior art keywords
alpha
connexin
seq
topical composition
polypeptide
Prior art date
Application number
RU2014139668A
Other languages
English (en)
Russian (ru)
Other versions
RU2014139668A (ru
Inventor
Гаутам ГХАТНЕКАР
Original Assignee
Ферстстринг Рисерч, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ферстстринг Рисерч, Инк. filed Critical Ферстстринг Рисерч, Инк.
Publication of RU2014139668A publication Critical patent/RU2014139668A/ru
Application granted granted Critical
Publication of RU2657535C2 publication Critical patent/RU2657535C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
RU2014139668A 2012-03-01 2013-03-01 Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act) RU2657535C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261605528P 2012-03-01 2012-03-01
US61/605,528 2012-03-01
PCT/US2013/028727 WO2013131040A1 (en) 2012-03-01 2013-03-01 Topical gels containing alpha connexin c-terminal (act) peptides

Publications (2)

Publication Number Publication Date
RU2014139668A RU2014139668A (ru) 2016-04-20
RU2657535C2 true RU2657535C2 (ru) 2018-06-14

Family

ID=49083360

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014139668A RU2657535C2 (ru) 2012-03-01 2013-03-01 Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act)

Country Status (17)

Country Link
US (5) US8846605B2 (enExample)
EP (1) EP2819682B1 (enExample)
JP (1) JP6185937B2 (enExample)
KR (1) KR102038948B1 (enExample)
CN (1) CN104271142B (enExample)
AU (1) AU2013225716B2 (enExample)
BR (1) BR112014021653B1 (enExample)
CA (1) CA2866115C (enExample)
DK (1) DK2819682T3 (enExample)
IL (1) IL234380B (enExample)
IN (1) IN2014DN07420A (enExample)
MX (1) MX351881B (enExample)
NZ (1) NZ629769A (enExample)
RU (1) RU2657535C2 (enExample)
SG (1) SG11201405359YA (enExample)
WO (1) WO2013131040A1 (enExample)
ZA (1) ZA201406373B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2691647C1 (ru) * 2018-11-29 2019-06-17 Артем Иванович Трофименко Средство для профилактики образования патологических кожных рубцов

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
RU2657535C2 (ru) 2012-03-01 2018-06-14 Ферстстринг Рисерч, Инк. Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act)
US11246821B2 (en) * 2016-08-30 2022-02-15 Rohm And Haas Company Personal care composition
MX2019009753A (es) * 2017-02-16 2019-12-18 Firststring Res Inc Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
EP3574892A4 (en) * 2017-06-14 2020-08-12 Bio Solution Co., Ltd. COSMETIC COMPOSITION TO REDUCE WRINKLES OR INFLAMMATION, CONTAINING SUBSTANCE P
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR20210057072A (ko) * 2018-09-12 2021-05-20 퍼스트스트링 리서치 인코포레이티드 알파 코넥신 c-말단 펩타이드에 대한 나노 입자 제제 및 사용 방법
US11751056B2 (en) * 2020-08-31 2023-09-05 Oracle International Corporation Methods, systems, and computer readable media for 5G user equipment (UE) historical mobility tracking and security screening using mobility patterns
CA3196342A1 (en) 2020-10-22 2022-04-28 Gautam Ghatnekar Peptide formulations and ophthalmic uses thereof
WO2023212446A1 (en) * 2022-04-29 2023-11-02 Xequel Bio, Inc. Compositions and methods for treating complications of viral infections and other respiratory disorders
CN117582401B (zh) * 2023-12-07 2024-04-26 唐宁医药科技(济南)有限公司 一种糖尿病足凝胶及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments
US20110300130A1 (en) * 2007-12-11 2011-12-08 Becker David L Impaired wound healing compositions and treatments

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3603444A1 (de) 1986-02-05 1987-08-06 Thomae Gmbh Dr K Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
NZ222413A (en) 1986-11-05 1991-06-25 Ethicon Inc Compositions containing a polypeptide growth factor and a water-soluble cellulose polymer stabiliser
US5234809A (en) 1989-03-23 1993-08-10 Akzo N.V. Process for isolating nucleic acid
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
US5401504B1 (en) * 1993-12-28 1998-04-21 Univ Mississippi Medical Cente Use of tumeric in wound healing
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
PT1146908E (pt) 1999-01-27 2005-10-31 David Dr Becker Formulacoes que contem nucleotidos de anti-sentido para conexinas
EP1178817A2 (en) 1999-05-14 2002-02-13 Arbor Vita Corporation Molecular interactions in haematopoietic cells
US7250397B2 (en) 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
WO2002042422A2 (en) 2000-11-10 2002-05-30 Arbor Vita Corporation Molecular interactions in hematopoietic cells
WO2002088370A2 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Autogene nucleic acids encoding a secretable rna polymerase
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US20050053918A1 (en) 2001-05-16 2005-03-10 Technion Research & Development Foundation Ltd. Method of identifying peptides capable of binding to MHC molecules, peptides identified thereby and their uses
CN1827766B (zh) 2001-06-28 2010-08-25 徐荣祥 体外细胞的培养方法
US6685971B2 (en) 2001-06-28 2004-02-03 Rongxiang Xu Method and composition for repairing and promoting regeneration of mucosal tissue in the gastrointestinal tract
AU2002321903A1 (en) 2001-08-03 2003-02-24 Arbor Vita Corporation Molecular interactions in cells
CA2461542A1 (en) 2001-10-17 2003-04-24 Tudor Morley Griffith Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
JP2003238441A (ja) 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
US7560430B2 (en) 2003-02-14 2009-07-14 Human Matrix Sciences, Llc Elastin digest compositions and methods utilizing same
AU2004294824A1 (en) 2003-12-03 2005-06-16 Coda Therapeutics (Nz) Ltd Antisense compounds targeted to connexins and methods of use thereof
ZA200706016B (en) * 2004-12-21 2008-12-31 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
EP2289535B8 (en) 2004-12-21 2018-08-08 MUSC Foundation for Research Development Compositions and methods for promoting wound healing and tissue regeneration
CA2596412A1 (en) 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
CA2612522A1 (en) * 2005-06-17 2006-12-28 Regenerx Biopharmaceuticals, Inc. Lkktet and/or lkktnt peptide compositions and methods
CN101198346A (zh) * 2005-06-17 2008-06-11 雷金纳克斯生物制药公司 Lkktet和/或lkktnt肽组合物及方法
US8128947B2 (en) * 2005-10-11 2012-03-06 Dpt Laboratories, Ltd. Surfactant-free dispersions, compositions, and use in topical formulations
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
KR20150072458A (ko) 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
RU2521329C2 (ru) 2006-12-11 2014-06-27 Коуда Терапьютикс, Инк. Композиции и способы лечения плохо заживающих ран
US20110130345A1 (en) 2007-06-21 2011-06-02 Baerbel Rohrer Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration
CA2592285C (en) 2007-06-28 2019-10-01 Musc Foundation For Research Development Compositions comprising connexin polypeptides and methods for promoting wound healing and tissue regeneration using connexin polypeptides
CN101970663A (zh) 2007-12-11 2011-02-09 科达治疗公司 受损伤口愈合的组合物和治疗
CA2710382A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
EP2252690A2 (en) 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
US20130184220A1 (en) 2007-12-21 2013-07-18 Bradford James Duft Treatment of abnormal or excessive scars
CA2710375A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
CA2710387A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of fibrotic conditions
EP2237796A2 (en) 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
WO2009085270A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions
EP2252689A2 (en) 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of surgical adhesions
JP2011524345A (ja) 2008-06-04 2011-09-01 コーダ セラピューティクス， インコーポレイテッド ギャップジャンクション調節化合物を用いる疼痛の治療
EP2586436A1 (en) 2011-10-31 2013-05-01 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
RU2657535C2 (ru) 2012-03-01 2018-06-14 Ферстстринг Рисерч, Инк. Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
US20110300130A1 (en) * 2007-12-11 2011-12-08 Becker David L Impaired wound healing compositions and treatments
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CONSOLE S., et al., Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans.J Biol Chem. 2003 Sep 12;278(37):35109-14. Epub 2003 Jun 30. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2691647C1 (ru) * 2018-11-29 2019-06-17 Артем Иванович Трофименко Средство для профилактики образования патологических кожных рубцов

Also Published As

Publication number Publication date
EP2819682A4 (en) 2016-01-06
US20150018284A1 (en) 2015-01-15
BR112014021653A2 (pt) 2022-05-10
KR20140132388A (ko) 2014-11-17
HK1205451A1 (en) 2015-12-18
CN104271142B (zh) 2017-07-04
AU2013225716B2 (en) 2017-10-12
MX351881B (es) 2017-11-01
CA2866115A1 (en) 2013-09-06
IL234380B (en) 2020-10-29
EP2819682A1 (en) 2015-01-07
JP6185937B2 (ja) 2017-08-23
JP2015513549A (ja) 2015-05-14
CA2866115C (en) 2020-03-24
SG11201405359YA (en) 2014-09-26
AU2013225716A1 (en) 2014-09-18
US10632173B2 (en) 2020-04-28
US20230263857A1 (en) 2023-08-24
US9161984B2 (en) 2015-10-20
BR112014021653B1 (pt) 2023-03-28
WO2013131040A1 (en) 2013-09-06
ZA201406373B (en) 2015-12-23
US20160058834A1 (en) 2016-03-03
MX2014010501A (es) 2015-03-09
IN2014DN07420A (enExample) 2015-04-24
DK2819682T3 (en) 2017-08-21
US11524049B2 (en) 2022-12-13
US8846605B2 (en) 2014-09-30
CN104271142A (zh) 2015-01-07
KR102038948B1 (ko) 2019-11-26
RU2014139668A (ru) 2016-04-20
US20130267471A1 (en) 2013-10-10
EP2819682B1 (en) 2017-05-03
NZ629769A (en) 2016-09-30
US12128086B2 (en) 2024-10-29
US20210128682A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
RU2657535C2 (ru) Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act)
KR20190135470A (ko) 방사능 상해 방지 및 조직 재생 촉진을 위한 조성물 및 방법
CA3054788A1 (en) Stabilized external use agent comprising thymosin beta-4 as effective ingredient
JP2018130552A (ja) 胆汁漏の処置
US20190292226A1 (en) Sap and peptidomimetic compositions for reducing symptoms of inflammation
KR20080031405A (ko) 상피 재생의 촉진
US20030004133A1 (en) Deepithelialized skin diffusion cell system
US5821220A (en) Method of producing concentrated non-buffered solutions of fibronectin
TW201204384A (en) Lactoferrin sequences, compositions and methods of wound treatment
JP7440126B2 (ja) 新生物性病変治療用ペプチド含有組成物
HK1205451B (en) Topical gels containing alpha connexin c-terminal (act) peptides
RU2772456C2 (ru) Композиции и способы для предотвращения радиационного поражения и стимуляции регенерации ткани
Patel et al. An in-situ forming controlled release soft hydrogel-based C5a peptidase drug delivery system to treat psoriasis